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Abstract
Background: B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50–60% of
patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identifying potential responders
prior to treatment. Positron emission tomography (PET) using radiolabeled rituximab for B-cell imaging might provide
the means to fulfil this unmet clinical need. The objective of this study was to investigate the association between
biodistribution of zirconium-89 (89Zr)-rituximab on PET-computed tomography (CT) and clinical response in
patients with RA.
Methods: We included 20 patients with RA who were starting rituximab treatment. At the first intravenous (i.v.)
therapeutic dose, patients were also injected with 89Zr-rituximab, followed by PET-CT. European League Against
Rheumatism (EULAR) response criteria were applied to determine response at week 24. PET-CT was analyzed
visually and quantitatively. Lymph node (LN) biopsies were performed at 0 and 4 weeks to correlate B-cell counts
with imaging data.
Results: PET-positive hand joints (range 1–20) were observed in 18/20 patients. Responders had significantly higher
89Zr-rituximab uptake in PET-positive hand joints than non-responders (median target-to-background (T/B)) ratios
(IQR) were 6.2 (4.0–8.8) vs. 3.1 (2.2–3.9), p = 0.02). At T/B ≥4.0, positive and negative predictive values for clinical
response were respectively 90% and 75%. Quantitative 89Zr-rituximab hand joint uptake on PET correlated
inversely with CD22+ B-cell count in LN tissue at 4 weeks of treatment (r = 0.6, p = 0.05). In addition, the CD22+
B-cell count in LN correlated positively with quantitative LN PET data at baseline, supporting the specificity of
B-cell imaging on PET.
Conclusions: Non-invasive B-cell imaging by 89Zr-rituximab PET-CT has promising clinical value to select RA
responders to rituximab at baseline. 89Zr-rituximab PET-CT may also hold promise for monitoring anti-B-cell therapies
in other B-cell driven autoimmune diseases, such as systemic lupus erythematosus and Sjögren’s disease.
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Background
B cells play an important role in the pathophysiological
process of rheumatoid arthritis (RA), presumably
through B-T-cell interaction and auto-antibody produc-
tion. Targeted depletion of B cells with a monoclonal
antibody (mAb) such as rituximab (anti-CD20) appears
to be efficient and cost-effective in patients with RA that
is refractory to disease-modifying anti-rheumatic drugs
(DMARDS) and anti-tumor necrosis factor-alpha therapy
(anti-TNF) [1–3]. Nevertheless, 30–50% of patients
with RA do not respond to rituximab [4, 5]. Treat-
ment could be more efficient if potential responders
to rituximab could be selected before treatment or
early during treatment.
Molecular imaging with positron emission tomography
(PET) might be a predictive tool for therapeutic out-
come in RA: PET allows non-invasive 3D visualization
and quantification of pathophysiological processes at the
picomolecular level, by binding of radiolabeled agents to
any affected tissue in the whole body [6]. Apart from
prediction of disease outcome in RA [7, 8], our group
has also previously demonstrated that PET predicts
infliximab outcome as early as two weeks after initiation
of treatment [9]. This predictive value for therapeutic
outcome was later confirmed by Roivainen et al. for
early DMARD combination treatment [10].
In our laboratory we have experience with good manu-
facturing practice (GMP)-labeling of mAbs with the PET
isotope Zirconium-89 (89Zr) [11, 12]. Zirconium-89 has
a physical half-life of about 78.4 hours and can be stably
coupled to mAbs. 89Zr-labeled rituximab has been suc-
cessfully applied for imaging and radioimmunotherapy
of CD20-positive B-cell lymphomas [13]. In fact, this
“immuno-PET” technique showed more tumor-positive
lymph nodes than the standard fluorodeoxyglucose (18F-
FDG; glucose metabolism) PET scans [13]. 89Zr-rituxi-
mab PET imaging may not only be interesting for
visualization of B cells in B-cell lymphoma but also for
other B-cell-related immune activity in the body. In RA,
apart from the joint synovium, studies have demon-
strated that B cells also play an important role in lymph
nodes in patients with RA [14–16].
Methods
In this study, we investigated whether in vivo biodistri-
bution of 89Zr-rituximab in RA, with special focus on
hand joints and lymph nodes, was associated with clin-
ical response to rituximab. We also collected lymph
node biopsies for analysis of B cells prior to rituximab
treatment, and after treatment with rituximab for
4 weeks, in order to investigate the potential associ-
ation between histological findings and imaging results.
Patients
Twenty rituximab-naïve patients with RA were included
between October 2010 and November 2014. Inclusion
criteria were: patients (>18 years of age) with at least
two clinically inflamed joints in the hands/wrists and a
clinical indication for rituximab treatment, and stable
treatment with DMARDs for at least 2 weeks and previ-
ous failure or intolerance to at least one anti-TNF drug.
Anti-TNF had to be discontinued at least 4 weeks before
initiation of rituximab treatment. Patients were not eli-
gible if being treated with >10 mg daily dose of prednis-
olone at the time of inclusion, if they had been treated
with investigational drugs within the previous 3 months
or if they were pregnant or breast-feeding. The study
protocol was approved by the VUmc Medical Ethics
Committee. All patients gave written informed consent
prior to participation in the study.
Study design
Rituximab treatment and administration of 89Zr-rituximab
The overall design of the study is shown in Fig. 1. In
concordance with routine clinical practice, patients re-
ceived two times 1000 mg rituximab at day 0 and at day
14, respectively. Premedication with intravenous (i.v.)
methylprednisolone was omitted to study the specific ef-
fects of rituximab on disease activity. Within one hour,
the first rituximab infusion was followed by infusion of
10 mg rituximab labeled with 18 mega Becquerel (MBq)
89Zr. The infusion system was flushed twice with 20 ml
NaCl 0.9% and residual activity in the administration
device was measured afterwards. Blood samples were
taken respectively at 5 minutes, 60 minutes and 72 hours
Fig. 1 Schematic overview of the study design. PET positron emission tomography, CT computer tomography
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and (in a subpopulation) 144 hours post injection (p.i.),
to determine 89Zr-rituximab kinetics based on measure-
ments of radioactivity in blood and plasma.
Synthesis of 89Zr-rituximab
We obtained 89Zr (2.7 GBq/mL in 1 M oxalic acid) from
Perkin Elmer (Boston, MA, USA). The 89Zr-Rituximab
was produced in a current Good Manufacturing
Practice (cGMP) compliant way in a facility with a
manufacturing license at the university campus
(Amsterdam, The Netherlands) essentially the same
as described before [13, 17].
PET-CT scanning
PET-CT scans were performed three days after tracer
administration due to long residence time of intact
mAbs combined with the half-life of zirconium-89 of
78.4 hours [11] (see Additional file 1: Appendix A). In
addition, scans were performed 6 days p.i. in a sub-
population of six patients to investigate targeting of
89Zr-rituximab over time in relation to blood clearance. In
short, whole body and detailed scans of the hands/wrists
were obtained. The maximum total scan time was ap-
proximately 60–75 minutes per patient. All scans were re-
constructed according to international guidelines [18].
PET imaging analysis
Biodistribution and extra-articular uptake (e.g. lymph
nodes) as depicted with whole body PET was qualita-
tively interpreted by one experienced nuclear medicine
physician (OSH). Detailed images of the wrists/hands
were subsequently interpreted by two independent
readers (OSH and SBR) for PET positivity (dichotomous)
of metacarpophalangeal (MCP), proximal interphalan-
geal (PIP) and wrist joints (n = 22 in total per patient),
with an adjudicator (JvdL) in case of discrepancies. Visual
PET positivity was defined as clearly enhanced tracer
uptake in joints versus local background. All readers
were blinded to the clinical data.
For quantitative analysis, volumes of interest (VOIs)
were drawn using analyzing software developed in house
[18] with the low-dose CT as the anatomical reference.
Specific details are described in Additional file 1:
Appendix A. Essentially, to analyze 89Zr-rituximab bio-
distribution in the body, VOIs were drawn on the aortic
arch (representing blood pool activity), lymph nodes,
bone marrow, large joints and internal organs, using in-
house biodistribution standard operating procedures.
For the comparison of quantitative joint uptake in the
wrist/hands at PET with clinical follow up, VOIs were
drawn on top of the PET-positive joints. In addition,
the metacarpal bone was used as background to calcu-
late local target-to-background (T/B) ratios. To com-
pare quantitative uptake of visually PET-negative joints
we applied fixed-size VOIs. Such VOIs were drawn on
the wrists, MCP joints and PIP joints, centered in the
middle of the joint. Standardized uptake values (SUV)
were calculated, defined as radioactivity in the VOI nor-
malized for injected dose and patient weight.
Lymph node biopsy
Up to 2 weeks before and 4 weeks after initiation of ri-
tuximab treatment, lymph node biopsies were performed
as described previously [19]. In short, an accessible
lymph node in the inguinal region was selected by ultra-
sound examination. In arthritis of the knee or ankle,
joint lymph node biopsies were performed on the ipsilat-
eral side. After the incision, needle biopsies were ob-
tained using a semi-automated biopsy gun and six to
eight biopsies were obtained and processed immediately
for immunohistochemical (IHC) analysis.
IHC analysis of lymphoid tissue sections
For detailed information see Additional file 2: Appendix B.
Basically, for IHC analysis, the lymph node tissue sections
were stained using mouse mAbs against B cells (CD22), T
cells (CD3), and plasma cells (CD138). CD22 was used as
the Bcell marker instead of CD20 because of the potential
blockade of CD20 receptors during rituximab treatment.
Staining was analyzed by digital image analysis as de-
scribed previously [20] and the number of positive cells
was calculated as the number of positive cells per
square millimetre of stained lymphoid tissue section.
Clinical follow up
Clinical follow up was performed at 24 weeks. Data col-
lected included disease activity score of 28 joints (DAS28),
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and Health Assessment Questionnaire (HAQ) at
baseline and week 24. A joint was defined clinically active
if tenderness and/or swelling were present on clinical
examination. All clinical data were obtained by an experi-
enced research nurse blinded to the imaging data. Re-
sponse to rituximab treatment was defined based on the
response criteria of the European League Against
Rheumatism (EULAR) at 24 weeks [21], and in this study
moderate responders were considered as responders. All
treating physicians were blinded to the imaging data.
Statistics
Data obtained by visual observation was analyzed in a
descriptive manner. Data are presented as mean ± stand-
ard deviation (SD) or as median and interquartile range
(IQR) in case of skewed distribution. The paired-sample
Wilcoxon signed-rank test, the Mann–Whitney U test
or Fisher’s exact test were used as appropriate. Correl-
ation between PET and clinical outcome parameters was
assessed using Spearman rank tests. A p value <0.05 was
Bruijnen et al. Arthritis Research & Therapy  (2016) 18:266 Page 3 of 8
regarded as statistically significant. Statistical analyses
were performed using SPSS version 20.0.0 for Windows
(SPSS, Chicago, IL, USA).
Results
Clinical data
PET-CT scans were obtained in 20 patients and lymph
node biopsies in 17 patients (Table 1). A complete set of
both PET-CT data and lymphoid tissue was collected in
14 patients. Apart from mild infusion-related reactions
(e.g. headache, transient drop in blood pressure) to the
therapeutic dose of rituximab, no serious side effects of
rituximab infusions were observed. 89Zr-rituximab was
injected without any side effects.
Baseline characteristics were comparable and no
significant differences were found between clinical and
serological data in responders and non-responders.
PET-CT analysis
Tracer joint uptake and clinical response
In 18/20 patients there was clearly enhanced uptake in
the joints of the wrists and hands, ranging from 1 to 20
joint(s) per patient (Fig. 2). Most (74%) of the PET-
positive joints also had clinical signs of arthritis. Visual
(dichotomous) interpretation of PET positivity in the
joints did not distinguish between clinical responders
and non-responders. Two patients who did not have
clear visual uptake in the peripheral joints were both
(moderate) responders.
Assessment in a subgroup of six patients with PET
data available at 3 and 6 days p.i., showed stable stan-
dardized uptake values (SUV) in the hand joints over
time. In contrast, a significant decrease of 25 ± 10.8% in
89Zr-rituximab was observed in the image-derived blood
pool over time, resulting in significantly increased
joint-to-blood ratios from a ratio of 0.4 to a ratio of
0.5 (p = 0.04). However, because of better count statis-
tics and qualitative images at day 3, the results pre-
sented subsequently apply to the 3-day p.i. data.
Quantitative analysis of the hand joints of all 20
patients showed a trend of higher 89Zr-rituximab joint
uptake in responders than in non-responders (SUV, p =
0.08; T/B ratio, p = 0.06). Moreover, among patients
with at least one PET-positive joint after visual screen-
ing (n = 18), mean quantitative 89Zr-rituximab uptake
in PET-positive hand joints per patient was significantly
higher in responders vs. non-responders with respect-
ively a mean SUV of 3.0 (2.5–3.5) vs. 1.9 (1.0–2.5) (p =
0.04). The majority of non-responders (6/7) had a mean
SUV value below ≤2.5 in visual PET-positive joints,
Table 1 Baseline patient demographics, clinical and functional characteristics
Responders (n = 13) Non-responders (n = 7) P value
Female, number (%) 12 (92) 6 (86) 0.589
Age, years 51.8 ± 13.3 54.4 ± 5.5 0.621
Length, cm 165.8 ± 8.7 166.6 ± 6.7 0.835
Weight, kg 71.2 (62.5–89.7) 70.0 (57.0–91.0) 0.643
IgM RF positivity, number (%) 10 (77) 5 (71) 0.594
RF titer, IU/mL 10.0 (8.4–84.5) 25.0 (0.0–176.0) 0.765
Anti-CCP positivity, number (%) 9 (79) 5 (71) 0.664
aCCP titer, U/mL 27.0 (0.0–193.5) 82.0 (0.0–270) 0.757
Disease duration, years 8.0 (3.5–16.0) 9.0 (4.0–21.0) 0.757
Current smokers, number (%) 3 (23) 3 (43) 0.336
DAS28 5.6 (4.9–6.1) 5.0 (4.0–7.1) 0.643
Swollen joint count 11.0 (7.5–14.0) 11.0 (8.0–18.0) 0.938
Tender joint count 14.0 (6.5–16.0) 8.0 (0.0–20.0) 0.588
HAQ 1.4 (0.8–1.8) 1.1 (0.5–2.0) 0.938
VAS 60.0 (52.5–64.0) 70.0 (40.0–75.0) 0.485
CRP, mg/mLa 6.0 (2.8–18.0) 4.0 (2.5–32.0) 0.699
ESR, mm/h 21.0 (10.5–41.0) 12 (5.0–36.0) 0.485
DMARD use, number (%) 12 (92) 5 (71) 0.270
Prednisone, number (%) 6 (46) 2 (29) 0.642
Dosage in mg/day 5 (0.0–7.5) 7.5 (0.0–10.0) 0.438
Values are presented as mean ± SD or median (IQR). aCRP lower detection limit is 2.5 mg/mL. IgM RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide,
DAS28 disease activity score of 28 joints, HAQ health assessment questionnaire, VAS visual analogue scale for pain, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, DMARD disease-modifying anti-rheumatic drugs
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while the mean SUV values of responders was ≥2.5 in
9/11 patients. In line with the absolute quantitative
joint uptake of 89Zr-rituximab, responders had a higher
mean T/B ratio of PET-positive hand joints than non-
responders 6.2 (4.0–8.8) vs. 3.1 (2.2–3.9) (p = 0.02), with
a T/B ratio ≤4.0 for 6/7 non-responders (Fig. 3).
Interestingly, if quantitative analysis of the hand joints
was limited to the PET-positive joint with the highest
SUV, there were similar statistical differences in the SUV
and T/B ratio between responders and non-responders.
The significant differences between responders and non-
responders were independent of serological status. Al-
though exploratory, we further investigated the potential
diagnostic values of our findings. Using a cutoff value of
4.0 for the T/B ratio, positive predictive value (PPV) and
negative predictive value (NPV) for response in our co-
hort were respectively 90% (95% CI 55.5–99.8%) and
75% (95% CI 34.9–96.8%), at a sensitivity of 82% (95%
CI 48.2–97.7%) and specificity of 86% (95% CI 42.1–
99.6%) (Fig. 3).
Whole body 89Zr-rituximab biodistribution and clinical
response
Whole body PET-CT scans of all 20 patients showed
uptake of 89Zr-rituximab in liver, spleen, kidneys, blood
pool, and in large joints (e.g. shoulders) in 9 patients
(Figs. 4 and 5). There were no significant differences in
organ biodistribution between responders and non-
responders (data not shown, see Additional file 3:
Appendix C). Finally, quantitative PET measures in both
body organs and detailed hand joints did not correlate
with any clinical or laboratory baseline parameters,
which are summarized in Table 1.
PET imaging data of lymph nodes and histological
evaluation
Lymph node biopsies were obtained in 13/20 patients
and were compared to PET analysis. PET-positive lymph
nodes were observed in 9/20 patients with RA and a
lymph node biopsy was available in 6 of these patients.
No association was found between visual PET positivity
in lymph nodes and clinical response. Interestingly,
however, quantitative 89Zr-rituximab uptake in the
most clearly PET-positive lymph node (highest SUV per
patient) was associated with CD22+ B-cell count in
histological analysis of excised lymph nodes at baseline
(r = 0.829; p = 0.04; n = 6). Although no associations
were found between quantitative 89Zr-rituximab in
Fig. 2 Example of a 89Zr-rituximab positron emission tomography
(PET) image of the wrists/hands of a patient with rheumatoid
arthritis who had multiple PET-positive joints. Red arrow represents
one PET-positive joint (green/yellow). SUV standardized uptake values
Fig. 3 Target-to-background ratios of positron emission tomography (PET)-positive joints in relation to clinical response, in those patients who
had at least one PET-positive joint on visual interpretation
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lymph nodes on PET and CD22+ Bcell counts in excised
lymph nodes at 4 weeks of rituximab treatment, Bcell
counts in lymph nodes after 4 weeks treatment correlated
negatively with baseline mean quantitative 89Zr-rituximab
uptake in PET-positive hand joints (r = −0.6; p = 0.05).
Discussion
Our study is the first that applied novel, non-invasive
PET imaging of B cells by 89Zr-rituximab to investigate
whether biodistribution of rituximab at baseline is related
to clinical response to rituximab treatment. 89Zr-rituxi-
mab PET demonstrated clinically active joints, even partly
in clinically silent joints, and there was a significant associ-
ation between quantitative 89Zr-rituximab uptake in the
hand joints and clinical response to rituximab treatment
at 24 weeks. Moreover, by using a T/B cutoff value of 4.0
in PET-positive hand joints we found a potential positive
predictive value of 90% for clinical response after 24 weeks
rituximab treatment, while clinical and serological data
were not distinctive. Apart from quantitative differences
in joint uptake, there were no 89Zr-rituximab biodistri-
bution differences in the lymph nodes or internal organs
between responders and non-responders.
Specific targeting of B cells by 89Zr-rituximab was sup-
ported by positive associations between quantitative
lymph node PET data and baseline CD22+ cell count (as
a surrogate marker for B cells) in histological lymph
node analysis, and by positive associations between post-
treatment CD22+ B cells in lymph nodes and quantita-
tive 89Zr-rituximab uptake on PET in the hand joint.
These findings are in line with results from our col-
leagues, Jauw et al. who found that tumor uptake of 89Zr-
rituximab correlated positively with CD20 expression in
tumor biopsies in patients with diffuse, large Bcell lymph-
oma [22]. Other observations in this study also underlined
the specificity of targeting B cells. Besides retention of 89Zr-
rituximab in arthritic joints over time (while cleared from
blood), specificity of uptake of 89Zr-rituximab in arthritic
joints was also supported by our finding of significantly
higher 89Zr-rituximab uptake in the joints of responders vs.
non-responders, despite identical levels of disease activity at
baseline. The lack of association between lymph node
uptake on PET and clinical response may have been caused
by the limited spatial resolution of PET of 4 mm, thus,
positive lymph nodes may have been missed by PET.
Potentially, 89Zr-rituximab administration following
the therapeutic dose of rituximab could result in compe-
tition of CD20 binding in the target, although it was ad-
ministered within one hour. Nevertheless we chose this
design to show the biodistribution of rituximab as used
in the therapeutic setting in daily clinical practice. The
kinetics of antibody influx in inflammatory targets are
rather slow (from hours up to several days) [11], but par-
tial blockade of CD20 binding sites by unlabeled rituxi-
mab at the time of the labeled rituximab infusion cannot
be excluded. If therapeutic doses negatively influenced
binding of the tracer then we may even have underesti-
mated 89Zr-rituximab uptake in the synovium and lymph
nodes. On the other hand, targeting of 89Zr-rituximab in
the joints and lymph nodes may also be influenced posi-
tively by infusion of the therapeutic dose of rituximab
just prior to injection of labeled 89Zr-rituximab, as the
spleen has been recognized as the “sink” for rituximab
binding during the first passage in circulation [11, 13].
Therefore, after saturation of the spleen, more 89Zr-
rituximab may have become available for other CD20
targets such as the arthritic joints. For future clinical mAb
studies in RA, dose escalation studies could answer this
question and help define the optimal study design.
Fig. 4 Maximum intensity projection whole-body 89Zr-rituximab
positron emission tomography image, demonstrating the biodistribution
in a patient with rheumatoid arthritis
Fig. 5 89Zr-rituximab positron emission tomography image-computer
tomography image of a patient with rheumatoid arthritis, who had
enhanced uptake in an inguinal lymph node (red circle)
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The finding that PET imaging with a 89Zr-labeled thera-
peutic antibody is able to predict therapeutic response
of the antibody is in line with recent findings by Gebhart
et al. They showed that pre-treatment 89Zr-trastuzumab
imaging in combination with early 18F-FDG PET re-
sponse assessment after one cycle of trastuzumab was
promising for the identification of non-responders after
three cycles (PPV100% and NPV92%) in patients with
breast cancer [23].
There were 2 out of 20 patients in our study who did
not show any 89Zr-rituximab uptake in the joints despite
having a clinical response. The explanations for this may
be relatively low Bcell counts (these patients had ap-
proximately 1500 CD22+ cells/mm2 in the lymph nodes
vs. approximately 3000 cells/mm2 in PET-positive pa-
tients) and/or general low inflammatory activity in the
joints in these patients, even though they did not differ
clinically from other (PET-positive) responders. Finally,
PET scans may have been false negative in these two
patients.
Apart from 89Zr-rituximab PET, the serological sta-
tus (RF and/or anti-CCP) has previously also been
indicated as a potential predictive biomarker of
therapeutic response. A meta-analysis, analyzing four
placebo-controlled, phase II or phase III clinical trials,
indicates that seropositive patients respond better to
rituximab than seronegative patients [24]. We could
not confirm this in our cohort and this discrepancy
can be due to the relatively small sample size of this
study. Nevertheless, in this relatively small number of
patients, the PET approach did reveal the predictive
potential of 89Zr-rituximab PET imaging with discrim-
inative value between responders and non-responders
by demonstrating and quantifying the radiolabeled drug in
arthritic joints. Actually, the level of 89Zr-rituximab
uptake in the hand joints did not correlate with any
clinical or laboratory parameter at baseline. None of
the clinical or laboratory data collected at baseline in
our study differed between responders and non-
responders.
Conclusions
In conclusion, Bcell imaging in joints by 89Zr-rituximab
PET-CT showed a clear association with clinical re-
sponse at 24 weeks in patients with RA. This technique
has potential value to select potential responders before
initiation of rituximab treatment. This finding should be
validated in larger cohorts, also in relation to other po-
tential predictive biomarkers, in particular the
serological status. Potentially, non-invasive, whole body
89Zr-rituximab PET-CT also holds promise for stratifica-
tion and monitoring of anti-Bcell therapies in other
Bcell-driven autoimmune diseases, such as systemic
lupus erythematosus and Sjögren’s disease.
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